Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Drug Patent & Exclusivity Expiration Report - Week of April 28 2025

    2025-04-28

    This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 21 2025

    2025-04-21

    This week, there are 18 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's JULUCA, containing active ingredient DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JANSSEN PRODUCTS LP's EDURANT, containing active ingredient RILPIVIRINE HYDROCHLORIDE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - GILEAD SCIENCES INC's COMPLERA, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - CELATOR PHARMACEUTICALS INC's VYXEOS, containing active ingredient CYTARABINE; DAUNORUBICIN - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 14 2025

    2025-04-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC's KYPROLIS, containing active ingredient CARFILZOMIB - JANSSEN PRODUCTS LP's SYMTUZA, containing active ingredient COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - INCYTE CORP's PEMAZYRE, containing active ingredient PEMIGATINIB - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - RIGEL PHARMACEUTICALS INC's TAVALISSE, containing active ingredient FOSTAMATINIB DISODIUM - ASTRAZENECA PHARMACEUTICALS LP's TAGRISSO, containing active ingredient OSIMERTINIB MESYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 07 2025

    2025-04-07

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's INVOKAMET, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKAMET XR, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKANA, containing active ingredient CANAGLIFLOZIN - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - EISAI INC's DAYVIGO, containing active ingredient LEMBOREXANT - NOVARTIS PHARMACEUTICAL CORP's AFINITOR DISPERZ, containing active ingredient EVEROLIMUS - ASTRAZENECA PHARMACEUTICALS LP's KOSELUGO, containing active ingredient SELUMETINIB SULFATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    2025-03-31

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's WAINUA (AUTOINJECTOR), containing active ingredient EPLONTERSEN SODIUM - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - BIOXCEL THERAPEUTICS INC's IGALMI, containing active ingredient DEXMEDETOMIDINE HYDROCHLORIDE - PHARMAAND GMBH's RUBRACA, containing active ingredient RUCAPARIB CAMSYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 24 2025

    2025-03-24

    This week, there are 10 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - NALPROPION PHARMACEUTICALS LLC's CONTRAVE, containing active ingredient BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - WYETH PHARMACEUTICALS LLC's PROTONIX, containing active ingredient PANTOPRAZOLE SODIUM - PURDUE PHARMA LP's OXYCONTIN, containing active ingredient OXYCODONE HYDROCHLORIDE - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - BRISTOL MYERS SQUIBB CO's ZEPOSIA, containing active ingredient OZANIMOD HYDROCHLORIDE - VERITY PHARMACEUTICALS INC's TLANDO, containing active ingredient TESTOSTERONE UNDECANOATE - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - VIIV HEALTHCARE CO's VOCABRIA, containing active ingredient CABOTEGRAVIR SODIUM Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 17 2025

    2025-03-17

    This week, there are 9 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - SANTARUS INC's GLUMETZA, containing active ingredient METFORMIN HYDROCHLORIDE - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - INCYTE CORP's JAKAFI, containing active ingredient RUXOLITINIB PHOSPHATE - FRESENIUS KABI USA LLC's SMOFLIPID 20%, containing active ingredient FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - NOVEN PHARMACEUTICALS INC's XELSTRYM, containing active ingredient DEXTROAMPHETAMINE - NOBELPHARMA CO LTD's HYFTOR, containing active ingredient SIROLIMUS - NOVARTIS PHARMACEUTICALS CORP's LOCAMETZ, containing active ingredient GALLIUM GA-68 GOZETOTIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    2025-03-10

    This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025

    2025-02-24

    This week, there are 12 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - VIFOR PHARMA INC's VELTASSA, containing active ingredient PATIROMER SORBITEX CALCIUM - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More
  • Total 3 pages  Go to Page
  • Go